Femoral vascular complications following catheter ablation of atrial fibrillation

被引:23
作者
Prudente, Liza A. [1 ]
Moorman, J. Randall [1 ]
Lake, Douglas [1 ]
Xiao, Yuping [1 ]
Greebaum, Heather [1 ]
Mangrum, J. Michael [1 ]
DiMarco, John P. [1 ]
Ferguson, John D. [1 ]
机构
[1] Univ Virginia Hlth Syst, Charlottesville, VA 22908 USA
关键词
Atrial fibrillation; Catheter ablation; Femoral vascular complications; MAJOR HEMORRHAGE; RISK; MANAGEMENT; THERAPY; OUTPATIENTS; STATEMENT; PERSONNEL; EFFICACY; SAFETY; POLICY;
D O I
10.1007/s10840-009-9402-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Femoral vascular complications remain a significant complication of catheter ablation of atrial fibrillation as a result of peri-procedural anticoagulation protocols. We investigated the effect of three different anti-coagulation regimens on the incidence of femoral vascular complications following AF ablation over a 4 year period. We performed 603 catheter ablations in 539 patients from January 2004 to January 2008. All patients were started on coumadin immediately after procedure and received enoxaparin at 1 mg/kg 4 h post procedure and again 12 h later. Three protocols for enoxaparin, administered 12 hourly, were used post-procedure: Protocol A-1 mg/kg x ten doses; Protocol B-1 mg/kg x six doses, and Protocol C-0.5 mg/kg x six doses. We documented occurrence of femoral vascular complications prior to discharge and at the 1 month post-op visit using a prospective database. A femoral vascular complication was defined as hematoma requiring prolonged hospitalization, blood transfusion or surgical intervention. There were 21 femoral vascular complications during the study period. The rate of complication fell from 5.7% (protocol A) to 1.6% (protocol C) (p < 0.03). We attribute the decrease in complication rate to the shorter anticoagulation protocol, as the reduction remained significant regardless of variation in catheter sizes. There were no new cerebral vascular events with the lower enoxaparin protocols. A shorter course of post procedure anticoagulation protocol can reduce femoral complications without contributing to increased risk of thromboembolic events.
引用
收藏
页码:59 / 64
页数:6
相关论文
共 22 条
[1]   The activation of platelet function, coagulation, and fibrinolysis during radiofrequency catheter ablation in heparinized patients [J].
Anfinsen, OG ;
Gjesdal, K ;
Brosstad, F ;
Orning, OM ;
Aass, H ;
Kongsgaard, E ;
Amlie, JP .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 1999, 10 (04) :503-512
[2]   When should heparin preferably be administered during radiofrequency catheter ablation? [J].
Anfinsen, OG ;
Gjesdal, K ;
Aass, H ;
Brosstad, F ;
Orning, OM ;
Amlie, JP .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2001, 24 (01) :5-12
[3]  
Brindis R G, 2001, J Am Coll Cardiol, V37, P2240, DOI 10.1016/S0735-1097(01)01372-9
[4]   HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for personnel, policy, procedures and follow-up [J].
Calkins, Hugh ;
Brugada, Josep ;
Packer, Douglas L. ;
Cappato, Riccardo ;
Chen, Shih-Ann ;
Crijns, Harry J. G. ;
Damiano, Ralph J., Jr. ;
Davies, D. Wyn ;
Haines, David E. ;
Haissaguerre, Michel ;
Lesaka, Yoshito ;
Jackman, Warren ;
Jais, Pierre ;
Kottkamp, Hans ;
Kuck, Karl Heinz ;
Lindsay, Bruce D. ;
Marchlinski, Francis E. ;
McCarthy, Patrick M. ;
Mont, J. Lluis ;
Morady, Fred ;
Nademanee, Koonlawee ;
Natale, Andrea ;
Pappone, Carlo ;
Prystowsky, Eric ;
Raviele, Antonio ;
Ruskin, Jeremy N. ;
Shemin, Richard J. .
EUROPACE, 2007, 9 (06) :335-379
[5]   Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation [J].
Cappato, R ;
Calkins, H ;
Chen, SA ;
Davies, W ;
Iesaka, Y ;
Kalman, J ;
Kim, YH ;
Klein, G ;
Packer, D ;
Skanes, A .
CIRCULATION, 2005, 111 (09) :1100-1105
[6]   Long-term safety and efficacy of circumferential ablation with pulmonary vein isolation [J].
Cheema, Aamir ;
Dong, Jun ;
Dalal, Darshan ;
Vasamreddy, Chandrasekhar R. ;
Marine, Joseph E. ;
Henrikson, Charles A. ;
Spragg, David ;
Cheng, Alan ;
Nazarian, Saman ;
Sinha, Sunil ;
Halperin, Henry ;
Berger, Ronald ;
Calkins, Hugh .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2006, 17 (10) :1080-1085
[7]  
Chesebro JH, 1996, ARCH INTERN MED, V156, P409
[8]   Trans-septal catheterization in the electrophysiology laboratory - Data from a multicenter survey spanning 12 years [J].
De Ponti, R ;
Cappato, R ;
Curnis, A ;
Della Bella, P ;
Padeletti, L ;
Raviele, A ;
Santini, M ;
Salerno-Uriarte, JA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (05) :1037-1042
[9]   Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study [J].
DiMarco, JP ;
Flaker, G ;
Waldo, AL ;
Corley, SD ;
Greene, HL ;
Safford, RE ;
Rosenfeld, LE ;
Mitrani, G ;
Nemeth, M .
AMERICAN HEART JOURNAL, 2005, 149 (04) :650-656
[10]   Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice [J].
Ellis, Martin H. ;
Hadari, Ruth ;
Tchuvrero, Noa ;
Shapira, Shirley ;
Kovlenko, Irena ;
Kozmiakova, Mariana ;
Zissin, Rivka ;
Elis, Avishay .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2006, 12 (02) :199-204